National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA.
Neuropharmacology. 2011 Oct-Nov;61(5-6):967-74. doi: 10.1016/j.neuropharm.2011.06.025. Epub 2011 Jul 5.
Adenosine A(2A) receptors (A(2A)Rs) are highly concentrated in the striatum. Two pharmacological different functional populations of A(2A)Rs have been recently described based on their different affinities for the A(2A)R antagonist SCH-442416. This compound has high affinity for A(2A)Rs not forming heteromers or forming heteromers with adenosine A(1) receptors (A(1)Rs) while showing very low affinity for A(2A)Rs forming heteromers with dopamine D(2) receptors (D(2)Rs). It has been widely described that striatal A(1)R-A(2A)R heteromers are preferentially localized presynaptically in the glutamatergic terminals that contact GABAergic dynorphinergic neurons, and that A(2A)R-D(2)R heteromers are localized postsynaptically in GABAergic enkephalinergic neurons. In the present study we provide evidence suggesting that SCH-442416 also targets postsynaptic A(2A)R not forming heteromers with D(2)R, which are involved in the motor depressant effects induced by D(2)R antagonists. SCH-442416 counteracted motor depression in rats induced by the D(2)R antagonist raclopride at a dose that did not produce motor activation or that blocked motor depression induced by an A(2A)R agonist. Furthermore, we re-evaluated the recently suggested key role of cannabinoid CB(1) receptors (CB(1)Rs) in the effects of A(2A)R antagonists acting at postsynaptic A(2A)Rs. By recording locomotor activity and monitoring striatal glutamate release induced by cortical electrical stimulation in rats after administration of A(2A)R and CB(1)R antagonists, we did not find evidence for any significant role of endocannabinoids in the post- or presynaptic effects of A(2A)R antagonists. The present results further suggest the existence of at least two functionally and pharmacologically different populations of striatal postsynaptic A(2A)Rs.
腺嘌呤 A(2A)受体(A(2A)R)在纹状体中高度集中。最近根据它们对 A(2A)R 拮抗剂 SCH-442416 的不同亲和力,描述了两种药理学上不同功能的 A(2A)R 群体。该化合物对不形成异源二聚体或与腺苷 A(1)受体(A(1)R)形成异源二聚体的 A(2A)R 具有高亲和力,而对与多巴胺 D(2)受体(D(2)R)形成异源二聚体的 A(2A)R 显示出非常低的亲和力。已经广泛描述了纹状体中的 A(1)R-A(2A)R 异源二聚体优先定位于与 GABA 能 dynorphinergic 神经元接触的谷氨酸能末梢的突触前,并且 A(2A)R-D(2)R 异源二聚体定位于 GABA 能enkephalinergic 神经元的突触后。在本研究中,我们提供的证据表明,SCH-442416 还靶向不与 D(2)R 形成异源二聚体的突触后 A(2A)R,其参与由 D(2)R 拮抗剂诱导的运动抑制作用。SCH-442416 在不产生运动激活或阻断 A(2A)R 激动剂诱导的运动抑制的剂量下,拮抗由 D(2)R 拮抗剂 raclopride 诱导的大鼠的运动抑制。此外,我们重新评估了最近提出的大麻素 CB(1)受体(CB(1)R)在作用于突触后 A(2A)R 的 A(2A)R 拮抗剂的作用中的关键作用。通过在大鼠中给予 A(2A)R 和 CB(1)R 拮抗剂后,记录运动活性并监测皮质电刺激诱导的纹状体谷氨酸释放,我们没有发现内源性大麻素在 A(2A)R 拮抗剂的突触后或突触前作用中具有任何重要作用的证据。目前的结果进一步表明,纹状体突触后 A(2A)R 至少存在两种功能和药理学上不同的群体。